SCHEMBL5536403

SCHEMBL5536403

Cc1cc(Cl)c2oc(=O)[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.49
NOS2 P35228 4/20 0.49
NOS3 P29474 3/20 0.49
KMO O15229 1/20 0.47
LMNA P02545 2/20 0.41
CYP1A2 P05177 2/20 0.41
TSHR P16473 2/20 0.41
THPO P40225 2/20 0.41
BLM P54132 2/20 0.41
ADRA2A P08913 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GRIN2D O15399 4/20 0.40
GRIN3B O60391 4/20 0.40
GRIN1 Q05586 4/20 0.40
GRIN2A Q12879 4/20 0.40
GRIN2B Q13224 4/20 0.40
GRIN2C Q14957 4/20 0.40
GRIN3A Q8TCU5 4/20 0.40
HSD17B10 Q99714 2/20 0.40
CSNK2A2 P19784 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2149212 0.82 NOS1 (0.53) NOS1NOS2NOS3KMOLMNA
SCHEMBL30538008 0.81 KMO (0.47) NOS1NOS2NOS3KMOLMNA
SCHEMBL14746125 0.81 KMO (0.47) NOS1NOS2NOS3KMOLMNA
SCHEMBL10732234 0.81 CYP1A2 (0.52) NOS1NOS2NOS3KMOLMNA
SCHEMBL8572742 0.79 NOS1 (0.46) NOS1NOS2NOS3KMOLMNA
SCHEMBL5543671 0.78 NOS1 (0.49) NOS1NOS2NOS3KMOLMNA
SCHEMBL5536396 0.78 KMO (0.47) NOS1NOS2NOS3KMOLMNA
SCHEMBL5362090 0.78 KMO (0.47) NOS1NOS2NOS3KMOLMNA
SCHEMBL5540014 0.78 NOS1 (0.49) NOS1NOS2NOS3KMOGRIN2D
SCHEMBL2149726 0.76 KMO (0.50) NOS1NOS2NOS3KMOLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOS1 553/4885NOS2 610/4885NOS3 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.